Celbek, GökhanÖzşahin, MustafaUslu, MustafaÖnder, ElifKutlucan, AliBeşir, Fahri HalitAydın, Yusuf2020-04-302020-04-3020141058-2452https://doi.org/10.3109/10582452.2014.883031https://hdl.handle.net/20.500.12684/2619WOS: 000340826100016Background: Biphosphonates, especially alendronate, are used extensively and successfully for the treatment of osteoporosis. However, there are numerous recent studies that indicate low-energy subtrochanteric femoral fractures can be associated with long-term alendronate therapy. Findings: We present a 76-year-old female patient who has taken 70 mg alendronate per week for 7 years, and who presented with pain in the left thigh. Conclusions: The patient was diagnosed as atypical femoral fracture resulting from long-term alendronate use. The diagnosis and the treatment will be discussed with a review of the literature.en10.3109/10582452.2014.883031info:eu-repo/semantics/closedAccessAlendronateatypical femoral fracturehip fracturesosteoporosisosteoporotic fracturesArticle223322326WOS:000340826100016N/AQ4